SENORES · Healthcare · Drug Manufacturers - General
Composite scorecard: 60/100 — Quality 66 · Valuation 28 · Momentum 100
| Share price | ₹1,385.00 |
| Market cap | ₹6,529 Cr |
| P/E ratio | 53.8 |
| P/B ratio | 6.0 |
| ROCE | 15.6% |
| Book value | ₹235.10 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹633 Cr | ₹122 Cr | 27.0% |
| 2025 | ₹398 Cr | ₹58 Cr | 23.0% |
| 2024 | ₹215 Cr | ₹33 Cr | 19.0% |
| 2023 | ₹35 Cr | ₹8 Cr | 36.0% |
| 2022 | ₹14 Cr | ₹1 Cr | 14.0% |
Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally. It offers pharmaceutical solutions, such as analgesic/antipyretic, anesthetics and allied products, antibacterial/antibiotic, antiviral, antifungal, antioxidants, antineoplastic, blood line, cardiovascular, neurology, antacid, and vitamin and mineral preparation solutions; and analgesic/anti-inflammatory/antipyretic, anti-diabetic, antimalarial, neutral supplements, and urinary tract generics, as well as ma